InnoCan Pharma (FRA:IP40) Growth Rank: 4 (As of Aug. 04, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IP40 InnoCan Pharma Corp FRA:IP40
58 GF Score
Price €1.63
GF Value €9.48
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Growth Rank?

InnoCan Pharma FRA:IP40 +1.56% 58 Growth Rank is 4 as of Aug. 04, 2026, which is at its 10-year median of 4.00. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €9.48 (Possible Value Trap). The stock has 2 warning signs investors should review.

InnoCan Pharma has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

InnoCan Pharma Growth Rank Related Terms

FRA:IP40 vs PG, CL, KVUE: Growth Rank Comparison

For the Household & Personal Products subindustry, InnoCan Pharma's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCan Pharma Growth Rank vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Growth Rank distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's Growth Rank falls into.


FRA:IP40
58GF Score
InnoCan Pharma Corp FRA:IP40
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
InnoCan Pharma (FRA:IP40) has a Growth Rank of 4 as of Aug. 04, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on InnoCan Pharma and its competitors. This is near median its historical median of 4.00. Over the past decade, InnoCan Pharma's Growth Rank has ranged from 4.00 to 6.00.
Is InnoCan Pharma's Growth Rank too high?
InnoCan Pharma's current Growth Rank of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 6.00. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Growth Rank compare to PG and CL?
InnoCan Pharma's Growth Rank of 4 can be compared against companies in the Consumer Packaged Goods industry. Historically, InnoCan Pharma's own Growth Rank has ranged from 4.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Consumer Packaged Goods company?
A good Growth Rank depends on the Consumer Packaged Goods industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Growth Rank is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.48, compared to a current price of €1.63 — trading 82.9% below its estimated fair value. The current Growth Rank is 4, which is near median its 10-year median of 4.00. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Growth Rank is 4 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.63 is trading 82.9% below its estimated GF Value™ of €9.48. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Growth Rank: 4 (near median its 10-year median of 4.00)
  • GF Value™: €9.48 vs. price of €1.63 (82.9% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score

Get the complete analysis for FRA:IP40

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.63
Price
€9.48
GF Value